Skip to main content

Table 1 Randomized or prolonged therapy in older chemotherapy regimens

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

Trial N Treatment arm Completed treatment* PFS p OS P References
Smith 2001 308 3 vs 6 mytomicin/cisplatin/vinblastine 72% vs 31% 5 mo vs 5 0.4 6 mo vs 7 0.2 [13]
Socinski 2002 230 4 Carboplatin/Paclitaxel vs Carboplatin/Paclitaxel until PD 57% vs 42%receiving >4cycles# - - 6.6 mo vs 8.5 0.63 [14]
Von Plessen 2006 297 3 vs 6 Carboplatin/Vinorelbine 78% vs 54% 16 wks vs 21 0.21 28 w vs 32 0.75 [15]
Park 2007 314 4 vs 6 cycles platinum-based therapy 68% vs 92% 4.6 mo vs 6.2 0.001 14.9 mo vs 15.9 0.41 [16]
  1. PFS: progression free survival, OS: overall survival; PD: progressive disease; mo: months; wks: weeks;
  2. *Percentage of patients who received the all planned courses of therapy
  3. #the percentage of grade 2-4 neuropathy in four arm cycles was 19% versus 43% in eight arm cycles.